The U.S. Food and Drug Administration gave positive feedback to the design of AmpliPhi Biosciences’ two proposed clinical trials of its Pseudomonas aeruginosa-targeting treatment candidate AB-PA01, the company announced in a press release. P. aeruginosa is the major cause of lung infections in cystic fibrosis patients.
Cystic fibrosis guide to clinical trials
Last updated Aug. 5, 2025 by Agata Boxe
Fact-checked by Patrícia Silva, PhD
Although researchers have made significant progress with therapies for cystic fibrosis (CF), many aspects of the disease remain challenging to treat. Among them are worsening lung function and persistent lung infections, as well as other symptoms that affect daily life.
Scientists have been trying to address these issues through clinical trials, which test new therapies in people before they can be approved by the U.S. Food and Drug Administration (FDA) or regulatory agencies in other countries.
Joining a CF clinical trial can give you access to experimental treatments that may work for you while also helping researchers better understand CF.
However, if you’re considering joining a CF clinical trial, be sure to talk to your doctors first to determine whether it’s a safe and appropriate option for you.
What is a CF clinical trial?
Clinical trials for CF are research studies that examine new methods for treating, managing, or diagnosing CF. They’re usually done after lab and animal testing, helping scientists understand whether a CF therapy is safe and effective.
Clinical trials for CF can focus on:
- testing new medications to improve lung function or treat infections
- developing gene or mRNA therapies for CF
- studying treatments for specific symptoms, such as breathing or gastrointestinal issues
- assessing new diagnostic tools or imaging techniques.
There are different phases of CF clinical trials:
- Phase 1 trials typically test the safety and dosage of a treatment in a small group of people.
- Phase 2 trials usually assess the effectiveness of the treatment and continue safety monitoring.
- Phase 3 trials generally compare the new therapy with standard options or a placebo in a larger group of people.
- Phase 4 trials are done after FDA approval to monitor long-term effects in a real-world setting.
The benefits and risks of CF clinical trials
The progressive nature of CF may play a role in why someone would be open to accepting the risks involved in trials. Still, it is essential to carefully weigh those risks and benefits before considering potentially participating in one.
The benefits of CF clinical trials include:
- early access to promising new CF treatments
- a chance to try to manage your condition proactively
- contributing to the advancement of CF therapies for the broader community.
The risks of CF clinical trials include:
- potential side effects from the experimental treatment
- a possible lack of improvement or worsening of symptoms
- the possibility of receiving a placebo or standard treatment instead of the new therapy
- additional time for appointments, testing, or travel
- costs that may not be covered by insurance or the study sponsor.
Types of CF clinical trials
There are several types of CF clinical trials, each with a different focus. They can explore a range of treatment goals, such as:
- testing antibiotics, anti-inflammatory drugs, or therapies for chronic infections
- easing symptoms, such as those related to breathing or digestion
- evaluating lifestyle and rehabilitation interventions focused on exercise, airway clearance, or diet, among others
- using biomarkers or imaging to better understand CF progression or predict treatment response.
Some CF trials enroll people with specific genetic mutations, while others may target those who haven’t responded to existing CF therapies. Other trials may have different goals.
Where to find CF clinical trials
To learn more about ongoing or new clinical trials in cystic fibrosis, first speak with your CF doctors. Members of your healthcare team may be aware of trials through hospitals, research centers, or national networks. They can let you know if you may be a good candidate.
Publicly accessible websites and databases can also provide additional information.
For trials in the United States, you can consult these sources:
Sources for trial opportunities outside the U.S. include:
- the EU Clinical Trials Register
- the European Cystic Fibrosis Society
- CF Europe
- the CF Trust (UK)
- the ISRCTN Registry (UK)
- Cystic Fibrosis Australia
- Cystic Fibrosis Canada.
What to ask before joining a CF trial
Asking questions can help you decide whether or not to participate in a trial. You may find it helpful to know exactly what to ask your CF doctor, the research team, and yourself as you are exploring the process.
Questions for your CF doctor
Your doctor can answer general questions about CF trials, such as:
- Am I a suitable candidate for a CF clinical trial?
- Do you know of any clinical trials that would be appropriate for my disease stage and symptoms?
- Would trial participation affect my current CF treatment plan?
- What are the potential risks and benefits of the trial you may be recommending?
- What would the trial require in terms of treatment, travel, and time commitment?
Questions for the research team
More detailed questions can be asked of researchers running the trial:
- What kind of treatment will the trial be testing, and why do you think it will work?
- Are there any known side effects, and, if so, how can they be managed?
- Does this study involve a placebo or another CF treatment that is already on the market?
- What are the odds of receiving a placebo or another CF treatment versus the new treatment?
- Who will cover the costs of my participation in the trial, and do I need insurance?
Asking about potential costs is especially important. Although most trials tend to cover the costs of the experimental treatment and any related medical care, that may not be the case for every single study.
If you are insured, you might want to ask your insurer whether or not the company can pay for your participation in the study, as well as care for potential side effects.
Questions to ask yourself
Participating in a clinical trial is a personal decision that should be made with careful consideration.
These self-reflective questions may help you make a decision:
- How do I hope to benefit from the trial, and are my expectations realistic?
- Am I willing to accept the risks, such as potential side effects or a chance of receiving a placebo?
- How may this trial affect my daily life?
- Am I willing to accept the time commitment and potential travel and expenses related to the trial?
- Do I feel ready to manage the emotional impact if the new treatment doesn’t work for me?
Additional information about CF clinical trials
CF clinical trials can provide a chance to try experimental treatments and give you more of a voice in your CF care. However, it is essential to keep in mind that these studies are not suitable for everyone, so it’s important to take the time to understand their risks and benefits.
Prioritize talking to your CF doctors first, so they can help you decide whether a CF trial is an option for you. And don’t hesitate to ask questions and advocate for yourself as you make this and other key decisions about your health and future.
Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Clinical trial news
Vertex Pharmaceuticals has completed enrollment for two Phase 3 studies testing the triple combination therapy of its new CFTR corrector VX-659 together with tezacaftor (VX-661) and Kalydeco (ivacaftor) in patients with cystic fibrosis (CF). The studies focus on patients with two F508del mutations in the CFTR gene (the…
Up to one month of treatment with inhaled vancomycin, the antibiotic of choice for treating most methicillin-resistant Staphylococcus aureus (MRSA) infections, together with a combination of oral and topical antibiotics, failed to clear infection in cystic fibrosis (CF) patients at better rates than the antibiotic combination alone, results from a Phase 2 clinical…
Mologic, an U.K.-based company developing personalized diagnostic devices, announced the beginning of a Phase 1/2 clinical trial to test its urine-based diagnostic tool, HeadsUp, to monitor pulmonary exacerbations in patients with cystic fibrosis (CF). The study is designed to identify biomarkers, present in urine of CF adult patients, that…
Topline data from a Phase 2b trial showed that the investigative therapy acebilustat taken once daily can reduce the number and frequency of pulmonary exacerbations in patients with cystic fibrosis (CF). It did not, however, seem to affect patients’ overall lung function. Pulmonary exacerbations — temporary worsening of lung function — are…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Experimental CF therapy SPL84 granted priority status in Europe
- I’m confident we will one day have a cure for cystic fibrosis
- Medications gave my daughter a measure of control, but never freedom
- Trikafta modestly eases digestive symptoms in children with CF: Study
- I am excited and anxious to finally meet my donor family